ಬಿಜಿ ನಗರದಲ್ಲಿ ಹಾಪ್‍ಕಾಮ್ಸ್ ಮಳಿಗೆ ಉದ್ಘಾಟಸಿದ ಸಚಿವ ನಾರಾಯಣಗೌಡ
ನಾಗಮಂಗಲ: ತಾಲ್ಲೂಕಿನ ಬಿಜಿ ನಗರದಲ್ಲಿರುವ ಆದಿಚುಂಚನಗಿರಿ ಆಸ್ಪತ್ರೆ ಮುಂಭಾಗ ನೂತನ ಹಾಪ್ ಕಾಮ್ಸ್ ಮಳಿಗೆಯನ್ನು ಸಚಿವ ನಾರಾಯಣ ಗೌಡ ಉದ್ಘಾಟಿಸಿದರು.
ಉದ್ಘಾಟನೆ ಕಾರ್ಯಕ್ರಮದ ನಂತರ ಮಾತನಾಡಿದ ಸಚಿವ ನಾರಾಯಣಗೌಡ ರವರು ಸಿದ್ದರಾಮಯ್ಯನವರ ಆರೋಪ ಸತ್ಯಕ್ಕೆ ದೂರವಾದ ಮಾತು ಕೊರೊನಾ ಸುರಕ್ಷತಾ ವಸ್ತುಗಳನ್ನು ಖರೀದಿ ಮಾಡುವಾಗ ಸರ್ಕಾರ ಯಾವುದೇ ಮೋಸದ ಕೆಲಸ ನಡೆಸಿಲ್ಲ. ಯಾರಾದರೂ ತನಿಖೆ ಮಾಡಲಿ, ವಿರೋಧ ಪಕ್ಷದವರಿಗೆ ಮಾಡಲು ಏನೂ ಕೆಲಸವಿಲ್ಲದೇ ಸರ್ಕಾರದ ಮೇಲೆ ಆರೋಪ ಮಾಡುತ್ತಿದ್ದಾರೆ. ಸರ್ಕಾರ ಕೊರೊನಾಗಾಗಿ ಕೇವಲ 600 ಕೋಟಿ ಖರ್ಚು ಮಾಡಿದೆ. ವಿರೋಧ ಪಕ್ಷದವರು ಸರ್ಕಾರ 2-5 ಸಾವಿರ ಕೋಟಿ ಎಂದು ಹೇಳುತ್ತಿದ್ದಾರೆ.ಇದು ನಂಬಲು ಸಾಧ್ಯವಿಲ್ಲದ ಇದು ಸುಳ್ಳು ಆರೋಪ. ವಿರೋಧ ಪಕ್ಷದವರು ಆರೋಪ ಮಾಡುವ ಬದಲು ಕೊರೊನಾ ನಿಯಂತ್ರಣದಲ್ಲಿ ಭಾಗವಹಿಸಿದರೆ ಖುಷಿಯಾಗುತ್ತದೆ. ಮುಖ್ಯಮಂತ್ರಿಗಳು ಯಾವುದೇ ಅಕ್ರಮ ನಡೆಯಲು ಅವಕಾಶ ನೀಡಿಲ್ಲ, ನೀಡುವುದಿಲ್ಲ ಎಂದರು.
ಅಲ್ಲದೇ ಈಗ ಬರುತ್ತಿರುವ ಕೊರೊನಾ ಸುರಕ್ಷತಾ ವಸ್ತುಗಳು ಗುಣಮಟ್ಟದಾಗಿದ್ದು, ಸರ್ಕಾರಕ್ಕೆ ಯಾರು ಸಹ ಅನ್ಯಾಯ ಮಾಡಿಲ್ಲ. ಪ್ರಾರಂಭದಲ್ಲಿ ಚಿಕ್ಕ ತಪ್ಪು, ವ್ಯತ್ಯಾಸವಾಗಿರಬಹುದು.ಅದನ್ನು ಬಿಟ್ಟರೆ ಸರ್ಕಾರ ಜವಾಬ್ದಾರಿಯಿಂದ ನಡೆಯುತ್ತಿದೆ. ಕೋವಿಡ್ ನಿಯಂತ್ರಣದಲ್ಲಿ ತಾಲ್ಲೂಕು ಆಡಳಿತ ದೊಂದಿಗೆ ಜಿಲ್ಲಾಡಳಿತಗಳು ಸಮರ್ಪಕವಾಗಿ ಕೆಲಸ ನಿರ್ವಹಿಸುತ್ತಿವೆ. ನಮ್ಮ ಜಿಲ್ಲೆಯ ಪ್ರದೇಶಗಳಲ್ಲೂ ಕೂಡ ಕೊರೊನಾ ಹರಡುತ್ತಿದ್ದು, ನಿಯಂತ್ರಣ ಕುರಿತು ಅಧಿಕಾರಿಗಳಿಗೆ ಸೂಚನೆ ನೀಡುತ್ತಿದ್ದೇನೆ. ಜೊತೆಗೆ ಪ್ರತಿ ತಾಲ್ಲೂಕಿನ ವಿವರವನ್ನು ದಿನನಿತ್ಯ ಪಡೆಯುವ ಮೂಲಕ ಸುಧಾರಣೆ ತರಲು ಕ್ರಮವಹಿಸುತ್ತಿದ್ದೇವೆ ಎಂದರು.
ನಂತರ ಆದಿಚುಂಚನಗಿರಿ ಆಸ್ಪತ್ರೆಗೆ ಭೇಟಿ ನೀಡಿದರು. ಆಡಳಿತ ಮಂಡಳಿಯವರು ರೋಗಿಗಳಿಗೆ ಉಚಿತ ಅಥವಾ ಸರ್ಕಾರದ ಪರಿಹಾರದೊಂದಿಗೆ ಪರೀಕ್ಷಿಸಲು ಅವಕಾಶ ನೀಡಬೇಕು ಎಂದು ಮನವಿ ನೀಡಿದರು. ಅದಕ್ಕೆ ಉತ್ತರಿಸಿದ ಸಚಿವರು ಖಾಸಗಿ ಆಸ್ಪತ್ರೆ ಕೋವಿಡ್ ಸೇವೆ ಮಾಡಲು ಬಂದಿರುವುದು ಪ್ರಮುಖ ವಿಷಯ. ಆದ್ದರಿಂದ ಜಿಲ್ಲಾಧಿಕಾರಿಗಳಿಗೆ ಬೇಗ ಅನುಮೋದನೆ ನೀಡುವಂತೆ ಸೂಚನೆ ನೀಡುತ್ತೇನೆ ಎಂದರು.
ವಿಧಾನ ಪರಿಷತ್ ಸದಸ್ಯ ಅಪ್ಪಾಜಿ ಗೌಡ,ತಹಶೀಲ್ದಾರ್ ಕುಂಞಿ ಅಹಮ್ಮದ್, ತಾಲ್ಲೂಕು ಆರೋಗ್ಯಾಧಿಕಾರಿ ಡಾ.ಧನಂಜಯ್, ತಾಲ್ಲೂಕು ಕಾರ್ಯನಿರ್ವಾಹಕ ಅಧಿಕಾರಿ ಅನಂತರಾಜು, ತೋಟಗಾರಿಕೆ ಇಲಾಖೆಯ ಹಿರಿಯ ಸಹಾಯಕ ನಿರ್ದೇಶಕಿ ಶಾಂತಾ ಮತ್ತು ಆಸ್ಪತ್ರೆ ಸಿಬ್ಬಂದಿ ಇದ್ದರು.
In view of sudden surge of COVID 19 cases in Bengaluru and on the advice of the experts, it is decided to impose lockdown for a period of one week in Bengaluru Urban and Rural Districts starting from 8 pm on Tuesday, 14th of July. Detailed guidelines will be issued on Monday in this regard.
During lockdown period, supply of essential commodities like groceries, vegetables, fruits, milk, medicines will continue uninterrupted. MBBS, post graduate examinations will be conducted as scheduled.
I appreciate the tireless efforts of our healthcare and police personnel, ASHA workers, volunteers and media persons in containing COVID 19 pandemic in the state.
I appeal people to cooperate with the Government, wear masks, maintain social distance, follow all guidelines, take all precautionary steps and help us contain the pandemic.
Thiruvananthapuram, July 2020: Pankajakasthuri Herbals India Private Limited (PKHIL) today announced promising interim clinical trial results for ZingiVir-H among patients suffering from COVID-19. Developed by Dr. J. Hareendran Nair, Founder of Pankajakasthuri Herbal Research Foundation, ZingiVir-H is a herbo-mineral drug made of a blend of seven ingredients. With the announcement, the company hopes to reiterate the tremendous potential of Ayurveda as a cost-effective and scalable solution to critical health conditions such as COVID-19.
Dr. J. Hareendran Nair, Founder and Managing Director, PKHIL, said, “Ayurveda has a long and storied tradition of helping treat a wide range of conditions, from everyday allergies to more complex ones such as autoimmune diseases. During such unprecedented times as now, where our immunity is critical to fighting a disease that has become a global pandemic, we believe that Ayurveda has the power to help develop an effective, cost-efficient and scalable treatment.”
Clinical trials of ZingiVir-H, Pankajakasthuri’s new drug, are underway among 112 patients as an adjunct therapy for the pandemic as well as among 135 additional patients as a stand-alone treatment in a double-blind study. The trials are progressing in 96 of the patients undergoing adjunct therapy. Out of these, the results of 42 patients are being published as an interim report. Among the 42 patients, 22 were treated with ZingiVir-H and 20 were treated with a placebo. It was found that all the 22 patients treated with ZingiVir-H were discharged on the fourth day after real-time Reverse Transcription Polymerase Chain Reaction (RT-PCR). The remaining 20 patients in the control group who received placeboes continued to be COVID-19+ve for 5 to 11 days.
“The results so far have been very positive and the trial is continuing,” said Dr. Nair. “We are equipped to provide the tablet as a treatment for COVID-19 across India and will collaborate with government bodies to ensure effective and quick distribution once the drug is approved. After this, we would also like to extend the treatment to regulators around the world for their respective countries. It is especially important to know that the use of the drug as a prophylactic treatment means that ZingiVir-H can help prevent the spread of COVID-19 and thereby prevent community transmission.”
ZingiVir-H tablets had obtained the Drugs License of the Government of Kerala and underwent cytotoxicity tests on human cells at the Rajiv Gandhi Center for Biotechnology and CSIR-NIIST at Thiruvananthapuram. After the animal studies were proved to be harmless, the clinical trial registration was obtained from the Clinical Trial Registry of India (CTRI). Thereafter, the drug was placed in Randomized Single Blind Placebo Controlled Multi-Center Clinical Trial as per World Health Organization (WHO)’s ICH-GCP standards at various medical colleges with approvals from respective ethical committees.
ZingiVir-H’s clinical trial is being conducted similar to the testing protocols in modern medicine. The results will be published after completion of the clinical trials and blood tests, including CRP, ESR, Interleukin, IgG and IgM, have proven the defensive functionality/efficacy of ZingiVir-H.
The interim clinical test results have been evaluated by a 5-member independent peer data monitoring committee (DMC). These included:
· The Chairman of the committee, Dr. V. Raman Kutty, Eminent Epidemiologist and data science expert, Research Director, Amala Cancer Research Centre, Thrissur. He is also a Former Emeritus Professor of Sree Chitra Tirunal Institute for Medical Sciences and Technology and Honorary Chairman, Health Action by People.
· Dr. K. P. Poulose, Former Professor, Kottayam Medical College & George Washington University, USA and Chief Physician, SUT Hospitals, Thiruvananthapuram;
· Dr. K. G. Raveendran, Retd. Medical Director, The Arya Vaidya Pharmacy, Coimbatore;
· Dr. V. S. SUGUNAN, Former Scientist C and Group Leader, Viral Hepatitis Laboratory, Rajiv Gandhi Center for Biotechnology, Thiruvananthapuram; and
· Dr. Asha Kamath, Associate Director, PSPH, Professor & Head, Department of Data Science, Manipal Academy of Higher Education.
Dr. Hareendran Nair also thanked the R&D head of Pankajakasthuri Dr. Shan Sashidharan and the Clinical Trial Coordinator Dr. K. P. Srinivasakumar, Head, Clinical Operations, Institute of Biology and Clinical Research, India, and others associated with it.
After the peer review from the DMC, the test results have been submitted for the approval by the Ministry of Ayurveda, Yoga & Naturopathy, Unani, Siddha and Homoeopathy (AYUSH).
ಬೆಂಗಳೂರು: ಸರ್ಕಾರಿ ಸೌಮ್ಯದ ಯೂನಿಯನ್‌ ಬ್ಯಾಂಕ್‌ ಆಫ್‌ ಇಂಡಿಯಾ ಎಂಸಿಎಲ್‌ಆರ್‌ (ನಿಧಿಯ ಕನಿಷ್ಠ ವೆಚ್ಚ ಆಧಾರಿತ ಸಾಲದರ) ವನ್ನು ಕಡಿತಗೊಳಿಸಿದೆ. ಶೇಕಡ 7.60 ರಷ್ಟು ಇದ್ದ ಎಂಸಿಎಲ್‌ಆರ್‌ ಈಗ ಶೇಕಡ 7.40 ಆಗಿದೆ. ಈ ದರವು ಜುಲೈ 11, 2020 ರಿಂದ ಅನ್ವಯವಾಗಲಿದೆ. ಜುಲೈ 2019 ರಿಂದ ಇಲ್ಲಿಯವರೆಗೆ ಬ್ಯಾಂಕ್‌ 13 ಬಾರಿ ರೇಟ್‌ ಕಟ್‌ ಘೋಷಿಸಿದೆ.
ಜಲೈ 11, 2020 ರಿಂದ ಅನ್ವಯವಾಗುವಂತೆ ಪರಿಷ್ಕೃತ ಎಂಸಿಎಲ್‌ಆರ್‌ ಹೀಗಿದೆ
Bengaluru: The Council for the Indian School Certificate Examinations, New Delhi has declared the results of ICSE class 10 exams today. A total of 2.06 lakh candidates are successful in the ICSE.
Making Bangalore proud, three students of Ekya School, JP Nagar, have scored 100 per cent in three subjects with all them scoring over 95% in Class 10 results. Another student has scored 100 per cent in two subjects. Thus, the school has four centurions.
Jahnavi Rajesh has scored 98%, Prasidh Padeep has 97.17% and Sushant R Naik has 95.50% with all them scoring Centum in History & Civics, Geography and Computer Applications.
Vaishnavi R with 96% has scored 100 percent in History & Civics and Aryan Kashyap Naveen scoring 96.00%. Another topper from Ekya School is Akash Chinni with 96.83%.
At all India level, as many as 54.19 per cent students who appeared for the exam were boys while 45.81 per cent were girls.
You must be logged in to post a comment.